Larch Arabinogalactan
Larch-bark soluble fiber: a gentle bifidogenic prebiotic best known for immune-modulating data
What is Larch Arabinogalactan?
Larch Arabinogalactan (Larix · ResistAid) is a prebiotic fiber used for bifidogenic / microbiome modulation: 15 g/day for 6 weeks lowered the fecal firmicutes:bacteroidetes ratio and trended toward higher bifidobacterium abundance in a crossover rct, with reduced putrefactive branched-chain scfas (isobutyrate/isovalerate). NutriDex grades the human evidence as Moderate. Larch arabinogalactan (LAG) is a highly water-soluble, branched polysaccharide extracted from the wood of larch trees (Larix), sold as the standardized ingredient ResistAid. It is selectively fermented in the colon by Bifidobacterium and other commensals, making it a true prebiotic, and unlike inulin it ferments slowly/distally so it is unusually well tolerated with little gas. The strongest randomized human data are for immune endpoints: at 1.5-4.5 g/day it boosted antibody responses to pneumococcal and tetanus vaccines and modestly reduced common-cold incidence, while a 15 g/day crossover RCT shifted the gut microbiome (lower Firmicutes:Bacteroidetes, trend toward more Bifidobacterium). Evidence for classic fiber outcomes (cholesterol, glucose, laxation) is thin to absent in humans, so its profile is more "immune-supportive prebiotic" than a cardiometabolic fiber.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Bifidogenic / microbiome modulation (↓Firmicutes:Bacteroidetes)Crossover RCT at 15 g/day lowered F:B ratio and trended to more Bifidobacterium; corroborated by ex vivo data. | Moderate | ↑ benefit · moderate | 2 |
| Enhanced vaccine antibody response (pneumococcal, tetanus)Two RCTs raised IgG to pneumococcal subtypes and tetanus; no effect on influenza-vaccine antibodies. | Moderate | ↑ benefit · moderate | 2 |
| Reduced common-cold incidenceOne RCT showed ~23% fewer cold episodes at 4.5 g/day; per-protocol significant, full-set borderline. | Preliminary | ↑ benefit · moderate | 1 |
| Innate immune stimulation (NK-cell activity)Small blinded trial raised activated NK cells in healthy subjects, but used a combination product. | Preliminary | ↑ benefit | 1 |
| GI tolerability (slow distal fermentation, low gas)Crossover RCT reports good GI tolerance with little gas versus rapidly fermented fibers. | Moderate | ↑ benefit · moderate | 1 |